Table 1 |
||||||||||||||
|
Characteristics of 1316 users and 2839 nonusers of hormone therapy |
||||||||||||||
|
Study |
Treatment |
n |
Mean age (years) |
Stage |
Nodal status |
ER status |
PgR status |
Mean DFI before HT (months) |
Estrogen alone (%) |
Mean duration of HT (months) |
Mean follow-up after HT (months) |
Recurrences (n) |
Deaths, all cause (n) |
Deaths, primary tumor (n) |
|
|
||||||||||||||
|
Randomized trials |
||||||||||||||
|
Marsden et al. (2000; n = 100) [20] |
HT |
51a |
58b |
NR |
NR |
NR |
NR |
40b |
NR |
6 |
NR |
2 |
NR |
NR |
|
No HT |
49a |
55b |
NR |
NR |
NR |
NR |
36b |
NR |
1 |
NR |
NR |
|||
|
Holmberg et al. (2004; n = 345) [9] |
HT |
174 |
55.5 |
NR |
25.9% (38) positive |
86 positivec |
NR |
31.2b |
NR |
24 |
25.2b |
26 |
5 |
3 |
|
No HT |
171 |
55.0 |
NR |
21.4% (31) positive |
73 positivec |
NR |
32.4b |
25.2b |
7 |
4 |
4 |
|||
|
Observational studies |
||||||||||||||
|
Ursic-Vrscaj and Bebar (1999; n = 63) [27] |
HT |
21d |
47b |
1 G1 10 G2 7 G3 |
14 negative, 7 positive |
5 positive, 16 negative |
8 positive, 13 negative |
62 |
4.8 |
28 |
38g |
4 |
0g |
0 |
|
No HT |
42d |
48.2 |
7 G1 17 G2 11 G3 |
28 negative 14 positive |
18 positive, 22 negative |
22 positive, 18 negative |
NR |
38g |
5 |
1g |
1 |
|||
|
DiSaia et al. (2000; n = 487) [22] |
HT |
125 |
55.7 |
17 DCIS 52 stage I 27 stage II 10 stage III 1 stage IV |
NR |
NR |
NR |
46b |
28 |
22b |
92.1g |
NR |
4g |
NR |
|
No HT |
362 |
55.9 |
NR |
NR |
NR |
NR |
NR |
90.6g |
NR |
57g |
NR |
|||
|
O'Meara et al. (2001; n = 869) [36] |
HT |
174d |
63.6e |
91 stage I 51 stage II 20 stage I/II 10 stage III 2 stage II/III |
128 negative, 31 positive |
84 positive, 39 negative |
71 positive, 45 negative |
47.7e |
79 |
15b |
44.4b,f |
16 |
17 |
5 |
|
No HT |
695d |
63.6e |
403 stage I 246 stage II 3 stage I/II 42 stage III 1 stage II/III |
470 negative, 175 positive |
409 positive, 137 negative |
311 positive, 206 negative |
47.7e |
44.4b,f |
101 |
115 |
59 |
|||
|
Beckmann et al. (2001; n = 185) [24] |
HT |
64 |
NA |
37 T1 19 T2 8 T3/4 |
44 negative, 20 positive |
31 positive, 33 negative |
34 positive, 30 negative |
0 |
NA |
33b |
37b |
6 |
4 |
NR |
|
No HT |
121 |
NA |
62 T1 42 T2 17 T3/4 |
76 negative, 45 positive |
48 positive, 73 negative |
48 positive, 73 negative |
0 |
42b |
17 |
15 |
NR |
|||
|
Marttunnen et al. (2001; n = 131) [26] |
HT |
88 |
53.4 |
3 DCIS 67 T1 17 T2 1 T3 |
72 negative, 10 positive |
57 positive, 15 negative |
54 positiveg, 13 negativeg |
50.4 |
38.6 |
30 |
30 |
7 |
2 |
2 |
|
No HT |
43 |
52.8 |
1 DCIS 29 T1 11 T2 2 T3 |
30 negative, 13 positive |
29 positive, 9 negative |
30 positiveg, 7 negativeg |
50.4 |
31.2 |
5 |
3 |
3 |
|||
|
Durna et al. (2002; n = 1122) [23] |
HT |
286 |
56.8b |
180 stage I 64 stage II 22 stage III/IV |
NA |
NR |
NR |
12b |
5.9 |
21b |
69.6b |
44 |
16 |
13 |
|
No HT |
836 |
64.7b |
470 stage I 191 stage II 120 stage III/IV |
NA |
NR |
NR |
NR |
61.2b |
247 |
199 |
122 |
|||
|
Vassilopoulou-Sellin et al. (2002; n = 299) [21] |
HT |
56h |
56b |
9 <1 cm 30 1–2.5 cm 15 >2.5 cm |
35 negative, 13 1–3, 6 >3 |
37 negative |
NR |
105.6 |
100 |
30 >5 years, 20 2–5 years, 6 2 years |
71 |
2 |
1 |
0 |
|
No HT |
243h |
53b |
38 <1 cm 134 1–2.5 cm 67 >2.5 cm |
133 negative, 70 1–3, 33 >3 |
164 negative |
NR |
99.6 |
NR |
33 |
2 |
1 |
|||
|
Decker et al. (2003; n = 554) [25] |
HT |
277 |
57.4b |
84 DCIS 124 stage I 47 stage IIA 19 stage IIB 3 stage IIIA |
NR |
100 positive, 54 negative |
63 positive, 46 negative |
43.3 |
48.7 |
44.4 |
49.7 |
30 |
7 |
5 |
|
No HT |
277 |
59.0b |
84 DCIS 124 stage I 47 stage IIA 19 stage IIB 3 stage IIIA |
NR |
121 positive, 35 negative |
73 positive, 42 negative |
NR |
45.6 |
35 |
17 |
9 |
|||
|
Summary |
||||||||||||||
|
Randomized trials |
HT |
225 |
56.07 |
38 positive |
86 positive |
33.19 |
19.92 |
25.20 |
28 |
5 |
3 |
|||
|
No HT |
220 |
55.00 |
31 positive |
73 positive |
33.20 |
25.20 |
8 |
4 |
4 |
|||||
|
Observational studies |
HT |
1091 |
56.98 |
293 negative, 87 positive |
277 positive, 194 negative |
230 positive, 147 negative |
37.70 |
40.4 |
28.02 |
57.46 |
109 |
51 |
25 |
|
|
No HT |
2619 |
60.87 |
737 negative, 350 positive |
625 positive, 440 negative |
484 positive, 346 negative |
54.01 |
57.02 |
443 |
409 |
195 |
||||
|
All combined |
HT |
1316 |
56.82 |
293 negative, 125 positive |
363 positive, 194 negative |
230 positive, 147 negative |
36.93 |
40.4 |
26.58 |
53.03 |
137 |
56 |
28 |
|
|
No HT |
2839 |
60.39 |
737 negative, 381 positive |
698 positive, 440 negative |
484 positive, 346 negative |
50.55 |
54.88 |
451 |
413 |
199 |
||||
|
|
||||||||||||||
|
aExcluding stage III/IV patients. bMedian value. cRefers to hormone receptor status; specific data concerning estrogen receptor (ER) and progesterone receptor (PgR) status were not reported. dExcluding patients with ductal carcinoma in situ (DCIS). eWeighted mean. fFor recurrence only; follow-up for mortality was 55.2 months. gPersonal communication. hExcluding DCIS, stages III and IV, and ER-positive patients. DFI, disease-free interval; HT, hormone therapy; NA, not able to calculate; NR, not reported. |
||||||||||||||
|
Col et al. Breast Cancer Research 2005 7:R535 doi:10.1186/bcr1035 |
||||||||||||||
